Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive developments in clinical trials and financial improvements, significant risks and challenges remain. The regulatory hurdles for enobosarm, bone density concerns, and intense market competition could weigh on investor sentiment. The Q&A session did not reveal any new risks, but the lack of profitability and the need for clear market advantages are concerns. The financial position shows improved cash reserves, but sustainability is uncertain. These factors balance each other out, leading to a neutral sentiment rating.
Key Financial Performance
Research and Development Costs $1.3 million, a decrease from $5.7 million year-over-year. The decrease is primarily due to the wind down of the Phase IIb quality clinical study for enobosarm, which was completed during fiscal 2025.
General and Administrative Expenses $4.1 million, a decrease from $5.2 million year-over-year. The decrease is primarily due to a reduction in share-based compensation.
Net Loss $5.3 million or $0.26 per diluted common share, compared to $8.9 million or $0.61 per diluted common share year-over-year. The improvement is attributed to reduced losses from discontinued operations and lower operating expenses.
Cash, Cash Equivalents, and Restricted Cash $33 million as of December 31, 2025, compared to $15.8 million as of September 30, 2025. The increase is due to proceeds from the sale of common stock and warrants in an underwritten public offering.
Net Working Capital $29.7 million as of December 31, 2025, compared to $11.1 million as of September 30, 2025. The increase is attributed to the cash inflow from the public offering.
Cash Used in Operating Activities $6.2 million for the 3 months ended December 31, 2025, compared to $11.3 million year-over-year. The reduction is due to lower operating expenses.
Net Cash Provided by Financing Activities $23.4 million for the 3 months ended December 31, 2025, compared to cash used of $4.2 million year-over-year. The increase is due to proceeds from the sale of common stock and warrants.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Enobosarm: An oral selective androgen receptor modulator (SARM) developed as a next-generation drug for obesity treatment. It aims to make weight reduction more tissue-selective, focusing on fat loss while preserving lean mass and physical function. Phase II QUALITY study demonstrated its effectiveness in combination with GLP-1 receptor agonists. It also prevents weight and fat mass regain after semaglutide discontinuation.
Sabizabulin: A microtubule disruptor being developed as a broad anti-inflammatory agent to reduce vascular plaque inflammation and slow the progression of atherosclerotic cardiovascular disease.
Regulatory Pathways for Enobosarm: FDA provided regulatory clarity for enobosarm development in combination with GLP-1 receptor agonists for obesity treatment. Two pathways include achieving at least 5% placebo-corrected weight loss or demonstrating clinically significant benefits like physical function preservation.
Bone Mineral Density (BMD) Endpoint: FDA's recognition of total hip BMD as a validated surrogate endpoint for drug development in postmenopausal women with osteoporosis is relevant for enobosarm's obesity program.
Phase IIb Plateau Clinical Study: A planned double-blind, placebo-controlled study to evaluate enobosarm's effects on weight, fat mass, lean mass, physical function, and bone mineral density in older patients with obesity. Expected to begin this quarter with interim analysis in early 2027.
Financial Highlights: Net proceeds of $23.4 million from a public offering in October 2025. Cash balance increased to $33 million as of December 31, 2025. Reduced R&D costs due to the completion of the Phase IIb QUALITY study.
Focus on Obesity Program: Shifted focus to developing enobosarm as a next-generation obesity treatment, leveraging its unique benefits in combination with GLP-1 receptor agonists.
Discontinued Operations: Sale of the FC2 Female Condom business to Clear Future Inc. in December 2024, allowing the company to concentrate on its biopharmaceutical developments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Pathways for Enobosarm: The development of enobosarm in combination with GLP-1 receptor agonist for obesity treatment faces regulatory challenges. The FDA has outlined two possible pathways for approval, both requiring stringent efficacy endpoints, which could delay or complicate the approval process.
Bone Mineral Density Concerns: GLP-1 receptor agonist therapy has been linked to reduced hip bone mineral density and increased risk of fractures, particularly in older patients. This poses a challenge for Veru's enobosarm program, as it must demonstrate clear benefits in improving bone health to address these safety concerns.
Weight Loss Plateau in Obesity Treatment: A significant challenge in obesity treatment is the weight loss plateau experienced by 88% of patients after one year on GLP-1 receptor agonists. Veru's enobosarm must prove its ability to overcome this plateau to be considered a viable solution.
Financial Sustainability: The company is not profitable and has negative cash flow from operations. Although recent financing has improved cash reserves, the sustainability of operations beyond the interim analysis of the Phase IIb PLATEAU clinical study remains uncertain.
Market Competition: The obesity treatment market is highly competitive, with established players like Novo Nordisk and Eli Lilly. Veru's enobosarm must demonstrate significant advantages over existing treatments to capture market share.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Development of enobosarm in combination with GLP-1 receptor agonist: The company plans to develop enobosarm in combination with GLP-1 receptor agonist for obesity treatment. FDA has provided regulatory clarity, confirming two possible pathways for approval based on incremental weight loss or clinically significant benefits in physical function. Enobosarm 3 mg is an acceptable dosage for future clinical development.
Phase IIb PLATEAU clinical study: The company plans to initiate a Phase IIb PLATEAU clinical study in Q1 2026 to evaluate enobosarm's effects on weight, fat mass, lean mass, physical function, and bone mineral density in older patients with obesity. Interim analysis is expected in Q1 2027.
Potential use of enobosarm for improving bone mineral density (BMD): Enobosarm may be developed to improve BMD in postmenopausal women with obesity receiving GLP-1 receptor agonist therapy, as FDA has validated total hip BMD as a surrogate endpoint for drug development in osteoporosis.
Future Phase III clinical studies: Future Phase III studies may use oral semaglutide in combination with oral enobosarm, leveraging data from the Phase IIb PLATEAU study.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why not use the oral semaglutide in the study instead of having optionality in Phase III?
A:The oral form of semaglutide is not exactly the same as the injectable form, which is slightly better. The goal is to minimize differences between the Phase IIb QUALITY study and the PLATEAU study. Using the injectable form ensures consistency and better outcomes. The oral form can be bridged later for safety testing, not efficacy.
Q:Did the FDA discuss the stair climb test and specific questionnaires as sufficient for the preservation of function endpoint?
A:Yes, the FDA discussed the stair climb test and emphasized conducting duplicate runs (loaded and unloaded) to normalize weight and challenge muscle. The stair climb test is sensitive to declines and anabolic intervention, making it a reliable measure. The Phase II study will also focus on patient-reported outcomes to assess clinical meaningfulness.
Q:Are there any prespecified decision rules for futility or sample size alteration in the interim analysis?
A:No, there are no futility analyses or sample size reestimations in the interim analysis. The primary endpoint is weight loss, and the interim analysis focuses on lean mass and fat mass to confirm the study's direction without taking a statistical penalty.
Q:What degree of weight loss is needed if assessing functional benefit with less than 5% weight loss?
A:If weight loss is less than 5%, it could still be acceptable if the physical function benefit is demonstrated. Approval could be based on functional benefit even if incremental weight loss is not observed.
Q:Review of Unclear Management Responses
A:None of the questions appeared to be avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BMD
Corporate Communications
DXA scan
Director Investor
Executive Director
FC Female
Female Condom
GLP receptor
III study
IIb PLATEAU
IIb plateau
Phase IIb
SELECT trial
Series warrant
agonist Phase
agonist treatment
combination GLP
endpoint enobosarm
enobosarm combination
enobosarm obesity
fracture
function bone
function weight
generation
hip
loss plateau
mass DXA
offering
osteoporosis
plateau study
scan endpoint
share stock
stock Series
stock warrant
treatment enobosarm
warrant share
VERU Transcript
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Unknown5-13
The earnings call summary reflects a negative sentiment due to declining revenue, decreased gross margin, and reduced net income, all of which are concerning for investors. The increased R&D expenses, while potentially beneficial in the long term, contribute to the current financial strain. The absence of strategic initiatives or positive guidance further exacerbates the negative outlook. Additionally, the lack of clarity in management's responses during the Q&A session adds to investor uncertainty, likely leading to a negative stock price movement in the short term.
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Unknown2-11
The earnings call presents a mixed picture. While there are positive developments in clinical trials and financial improvements, significant risks and challenges remain. The regulatory hurdles for enobosarm, bone density concerns, and intense market competition could weigh on investor sentiment. The Q&A session did not reveal any new risks, but the lack of profitability and the need for clear market advantages are concerns. The financial position shows improved cash reserves, but sustainability is uncertain. These factors balance each other out, leading to a neutral sentiment rating.
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Positive12-17
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Unknown8-12
The earnings call summary and Q&A indicate mixed signals. While the company shows progress in drug development and partnership discussions, financial health raises concerns due to insufficient cash for long-term operations and a significant net loss. The potential for new partnerships and an improved formulation could be positive, but financial constraints and the need for substantial capital for Phase III trials temper expectations. The market is likely to react cautiously, resulting in a neutral sentiment.
VERU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
